Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study
|
|
- Lynn Barrett
- 6 years ago
- Views:
Transcription
1 ARTICLES Electroconvulsive Therapy Augmentation in Clozapine-Resistant Schizophrenia: A Prospective, Randomized Study Georgios Petrides, M.D., Chitra Malur, M.D., Raphael J. Braga, M.D., Samuel H. Bailine, M.D., Nina R. Schooler, Ph.D., Anil K. Malhotra, M.D., John M. Kane, M.D., Sohag Sanghani, M.D., Terry E. Goldberg, Ph.D., Majnu John, Ph.D., Alan Mendelowitz, M.D. Objective: Up to 70% of patients with treatment-resistant schizophrenia do not respond to clozapine. Pharmacological augmentation to clozapine has been studied with unimpressive results. The authors examined the use of ECT as an augmentation to clozapine for treatment-refractory schizophrenia. Method: In a randomized single-blind 8-week study, patients with clozapine-resistant schizophrenia were assigned to treatment as usual (clozapine group) or a course of bilateral ECT plus clozapine (ECT plus clozapine group). Nonresponders from the clozapine group received an 8-week open trial of ECT (crossover phase). ECT was performed three times per week for the first 4 weeks and twice weekly for the last 4 weeks. Clozapine dosages remained constant. Response was defined as $40% reduction in symptoms based on the psychotic symptom subscale of the Brief Psychiatric Rating Scale, a Clinical Global Impressions (CGI)-severity rating,3, and a CGI-improvement rating #2. Results: The intent-to-treat sample included 39 participants (ECT plus clozapine group, N=20; clozapine group, N=19). All 19 patients from the clozapine group received ECT in the crossover phase. Fifty percent of the ECT plus clozapinepatientsmettheresponsecriterion.noneofthe patients in the clozapine group met the criterion. In the crossover phase, response was 47%. There were no discernible differences between groups on global cognition. Two patients required the postponement of an ECT session because of mild confusion. Conclusions: The augmentation of clozapine with ECT is a safe and effective treatment option. Further research is required to determine the persistence of the improvement and the potential need for maintenance treatments. Am J Psychiatry 2015; 172:52 58; doi: /appi.ajp As many as 30% of patients with schizophrenia respond poorly to standard treatment with antipsychotic medications (1). Clozapine is the only medication shown to be effective in antipsychotic-refractory patients (2, 3), but in as many as 45% to 70% of these patients, symptoms are also resistant to substantial improvement with clozapine (2, 4). Limited options are available for individuals with clozapine-resistant symptoms. Several augmentation strategies have been evaluated, including addition of another antipsychotic, mood stabilizers, anxiolytics, antidepressants, and glutamatergic agents; however, no agent has shown unequivocal efficacy in this population. Meta-analyses of randomized placebo-controlled studies have found little or no advantage of augmentation with antipsychotics (5 8). The treatment of this subgroup of patients remains an enormous challenge, with significant public health implications. Preliminary data from nonrandomized open-label studies suggest that addition of ECT may be an effective alternative for patients with clozapine-resistant symptoms. ECT, while initially introduced for the treatment of schizophrenia in the 1930s, is currently most commonly used for the treatment of depression. ECT and antipsychotics are considered to exhibit synergistic effects (9). In 36 patients with symptoms resistant to typical antipsychotics, Kupchik et al. (10) found that 67% of these patients benefitted from the combination of clozapine and ECT, clozapine, or ECT alone. In an open-label study in 11 clozapine nonresponders, Kho et al. (11) found the combination of clozapine plus ECT to be efficacious. Havaki-Kontaxaki et al. (12) reviewed all studies of clozapine-ect combination in schizophrenia or schizoaffective patients with strictly defined clozapine-resistant symptoms, concluding that preliminary evidence exists for This article is featured in this month s AJP Audio, is an article that provides Clinical Guidance (on the Table of Contents), and is discussed in a Video by Dr. Pine 52 ajp.psychiatryonline.org Am J Psychiatry 172:1, January 2015
2 PETRIDES ET AL. the safety and short-term efficacy of this combination. The main limitation of this review was the small sample size (N=21) with data from one open-label trial and six case studies. Finally, Masoudzadeh and Khalilian (13) compared ECT, clozapine, and ECT-clozapine combination in schizophrenia patients with treatment resistant symptoms and noted a Positive and Negative Syndrome Scale score reduction of 46% in the clozapine group, 40% in the ECT group, and 71% in the clozapine-ect group. They concluded that the combination was significantly better than either treatment alone. Therefore, our group initiated a pilot study of the effects of adding ECT to clozapine. In an open-label prospective study, we used bilateral ECT to treat 15 patients with schizophrenia who had not responded to clozapine or partially responded to clozapine, despite adequate doses for more than 12 weeks. Nine of these patients (60%) met the a priori response criterion of a 40% decrease in symptom ratings as measured by the psychotic symptom subscale of the Brief Psychiatric Rating Scale (BPRS) (14). Based on these encouraging preliminary data, we have now conducted the first prospective randomized study of the efficacy and side-effect profile of ECT plus clozapine in schizophrenia patients with clozapine-resistant symptoms. METHOD The study was conducted at The Zucker Hillside Hospital of the North Shore-LIJ Health System. The study was approved by the respective institutional review boards, and participants were recruited from the inpatient units of the Zucker Hillside Hospital at Glen Oaks, N.Y., and the Pilgrim State Psychiatric Center in Long Island, N.Y. Study Design and Procedures In an 8-week random-assignment study incorporating nonblinded treatment and blinded assessments, patients with antipsychotic- and clozapine-resistant schizophrenia were assigned to two treatment groups. One group received treatment as usual (clozapine group) for 8 weeks, and the other received a course of bilateral ECT in addition to their current pharmacotherapy regimen (ECT plus clozapine). Nonresponders from the clozapine group received an open 8-week trial of ECT (crossover trial) with the same schedule and procedures as the randomized ECT plus clozapine group. Antipsychotic medication resistance was defined as a history of at least two failed trials of 400 mg of chlorpromazine equivalents for at least 4 weeks. Clozapine resistance was defined as a history of persistence of psychotic symptoms after a trial of clozapine of at least 12 weeks, at a blood level $350 ng/ml. The inclusion criteria were diagnosis of schizophrenia according to DSM-IV criteria; age years; duration of illness.2 years; resistance to at least two antipsychotics; clozapine resistance; a baseline BPRS score of at least moderate (score of 4) on one of the four psychotic items (hallucinatory behavior, suspiciousness, conceptual disorganization, and unusual thought content) of the psychotic symptom subscale or a score of 12 on these four items combined; a Clinical Global Impressions (CGI)-severity (15) rating of at least moderate (score of 4); capacity to give informed consent; and for women of childbearing capacity, a negative pregnancy test and patient agreement to use a medically accepted form of contraception. Exclusion criteria were schizoaffective disorder; bipolar disorder; current affective episode; ECT within 6 months; history of epilepsy; severe neurological or systemic disorder that could significantly affect cognition, behavior, or mental status (other than tardive dyskinesia or neuroleptic-induced parkinsonism); psychoactive substance dependence (other than nicotine or caffeine) within 1 month prior to entering the study; a score.18 on the 24-item Hamilton Depression Rating Scale (HAM-D) (16); clinical determination that mood stabilizers that could not be discontinued were necessary; and pregnancy. We also excluded patients with affective disorders and prominent depressive symptoms because ECT is well known to be effective in those situations, and we wanted to avoid contamination of our results by improvement solely driven by the treatment of the affective symptoms. The primary outcome measure was response rate. The response criterion was defined a priori as improvement $40% based on the psychotic symptom subscale, a CGI-severity rating of mild or less (,3), and a CGI-improvement rating of much improved (#2). For power calculations, we assumed a response rate of 40% in the ECT plus clozapine group and 10% in the clozapine group. We chose to define response as a 40% reduction in symptoms based on the psychotic symptom subscale, compared with the traditional 20% in medication studies, recognizing that ECT adds additional levels of complexity and requires increased effort by both clinicians and patients. Clozapine Group Once randomly assigned, participants in both groups remained on the clozapine dose at which they entered the study for 8 weeks. Concurrent use of other antipsychotic medications and antidepressants was allowed as long as they were taken at a stable dose for at least 12 weeks before entering the study. Lorazepam, up to 6 mg per day, or diphenhydramine, up to 100 mg, were used as needed for anxiety, agitation, or insomnia. ECT Plus Clozapine Group ECT was performed with bilateral placement using the Thymatron-DGx device (Somatics, Lake Bluff, Ill.). Seizure threshold was determined at the first treatment. Dosing at subsequent treatments was given at 50% above threshold. The seizure threshold determination schedule and subsequent stimulus levels are shown in Table 1. Medications used during anesthesia were glycopyrrolate (0.1 mg 0.2 mg), methohexital (0.5 mg/kg 1 mg/kg), and succinylcholine (0.5 mg/kg 1 mg/kg). Participants signed a separate informed consent for ECT, and standard institutional procedures for ECT were followed. ECT was administered three times per week for the first 4 weeks, then twice weekly for the next 4 weeks. If patients Am J Psychiatry 172:1, January 2015 ajp.psychiatryonline.org 53
3 ECT AUGUMENTATION IN CLOZAPINE-RESISTANT SCHIZOPHERNIA TABLE 1. ECT Dosing Algorithm Seizure Threshold (% Energy) Dose at Subsequent Treatment (% Energy) met remission criteria before the completion of 8 weeks and showed a plateau in their improvement for two consecutive ratings, ECT was continued weekly through the end of 8 weeks. Crossover ECT Trial Participants from the clozapine group who did not respond to 8 weeks of continued pharmacotherapy received ECT augmentation with the same schedule of treatments and ratings as the ECT plus clozapine group for an additional 8 weeks. Assessments and Raters Eligible, consenting patients had a complete baseline medical and psychiatric evaluation. DSM-IV diagnosis was established using the Structured Clinical Interview for DSM-IV (17) by experienced raters. Patients were rated at baseline and weekly. Final rating assessments were performed at the end of week 8, except those from the cognitive battery, which was administered at week 9 (i.e., 1 week after the last ECT session). The raters were masked to the clinical assignment. Psychopathology rating measures included the BPRS, CGI, HAM-D, the Schedule for Assessment of Negative Symptoms (18), and the Treatment Emergent Side Effects Scale (15), and rating assessments were performed weekly. To enhance objectivity, we videotaped the initial (baseline) and final (week 8 or study exit) BPRS ratings. The tapes were edited to remove any revealing statements about treatment, and brief (2 5 seconds), nonessential portions from all tapes were erased to create 3 10 skips in a random fashion, thus balancing the presence of awkward skips that might be otherwise present mostly in the ECT tapes. An independent, masked rater rated the edited tapes. The average score between the two ratings at baseline and the last visit was used for data analyses. A focused neuropsychological battery was performed at baseline and at week 9. The battery was designed to assess ECT-related effects, as well as measures of cognition relevant to schizophrenia, and included the standard and modified Mini-Mental State Examination (MMSE), the Rey Auditory Verbal Learning Test, the paired-word and story-recall measures subtests of the Randt Memory Battery, the letter-number span task, the Trail-Making Test, the Controlled Oral Word Association Test, the Competing Programs Test, and the Set Shifting Test. Statistical Analysis Histograms, q-q plots, and the Shapiro-Wilk test were used to assess distribution of continuous variables. Based on the distribution, an independent-samples t test or Wilcoxon rank-sum test was used to compare the baseline continuous variables between treatment groups. Chi-square test was used for categorical variables. Since missing values may be dependent on the observed outcomes, we assumed the missing data to be missing at random, and hence analysis of the longitudinal data was conducted utilizing a mixed-models approach. A random intercept in the mixed-models was used to account for correlation of measurements over time among the participants; the correlational type was assumed to be unstructured. The difference in slopes of the outcomes between the two treatment groups was assessed using group-by-time interaction term in the mixed models. Interrater reliability between the in-person and video ratings was assessed using both consistency and absolute agreement intraclass coefficients. The consistency intraclass coefficient between the ratings was (95% confidence interval [CI]= ; F=17.5, df=28, 28, p,0.0001). The absolute agreement intraclass coefficient was (95% CI= ; F=17.5, df=28, 28, p,0.0001). All analyses were adjusted for age. RESULTS Participants Participant screening and enrollment flow data are presented in Figure 1 (92 were screened; 54 met inclusion criteria; 13 refused participation; 41 signed consent). Thirty-nine individuals were randomly assigned (ECT plus clozapine group, N=20; clozapine group, N=19). The two groups were well matched on demographic variables, including sex, ethnicity, and psychopathology (Table 2). However, the ECT-treated group was significantly younger than the clozapine group; therefore, all analyses were adjusted for age. Of the 20 participants assigned to ECT plus clozapine, 17 completed the 8-week trial, two dropped out early and refused further ECT treatments, and one was removed from the study because of persistence of involuntary movements. In the clozapine group, 16 of the 19 patients completed the 8-week clozapine phase, and three patients dropped out because they refused to continue to participate in the ratings assessment while there was no change in their treatment. However, all three of the patients who dropped out agreed to participate in the crossover ECT phase, and all 19 participants were included in that phase. Clinical Efficacy Results Ten of the 20 patients (50%) in the ECT augmentation and none (0%) of the patients in the clozapine group met the a priori response criterion. If the less conservative but commonly used response criterion of a 20% reduction in symptoms were used, we would have 12 (60%) responders. Conversely, if an even stricter criterion were used, such as a 50%, 60%, or 70% reduction in symptoms based on the psychotic symptom subscale, we would have nine (45%), six (30%), or three (15%) responders, respectively. None of the clozapine patients would have responded with any of the above criteria. Patients randomly assigned to ECT augmentation were found to have significantly greater reduction in ratings on the BPRS-psychosis 54 ajp.psychiatryonline.org Am J Psychiatry 172:1, January 2015
4 PETRIDES ET AL. FIGURE 1. CONSORT Diagram for Patients With Clozapine-Resistant Schizophrenia Screened (N=92) Met screening criteria (N=54, 59%) Signed informed consent (N=41) Randomly assigned (N=39) Refused study procedures (N=2) ECT (N=20, 51%) Completers (N=17) Early termination (N=3) No ECT (N=19, 49%) Completers (N=16) Early termination (N=3) Responders (N=10, 50%) Nonresponders (N=10, 50%) Responders (N=0, 0%) Nonresponders (N=19, 100%) ECT: nonrandomized (N=19) Responders (N=9, 47%) Nonresponders (N=10, 53%) subscale and the CGI-severity scale compared with patients in the clozapine group over time (Figure 2, Figure 3). Post hoc analyses revealed that the ECT plus clozapine group had significantly lower psychotic symptom subscale ratings by week 3, and this significant difference persisted for the remainder of the 8-week trial. In the crossover phase, nine (47.4%) of 19 patients met the response criterion. Overall, of the 39 patients who received ECT in the randomized and crossover arms, 19 (48.7%) had at least a 40% reduction in ratings on the psychotic symptom subscale after 8 weeks of treatment. Regarding negative symptoms, there were no significant differences between the two groups and in group-by-time interactions in analyses with the Scale for the Assessment of Negative Symptoms on global measures for affective flattening (F=0.98, df=1, 39.3, p=0.33), alogia (F=0.03, df=1, 40.1, p=0.87), avolition-apathy, (F=0.76, df=1, 39.3, p=0.39), and anhedoniaasociality (F=1.87, df=1, 39.7, p=0.18). The above analysis was based on actual differences from baseline to final visit. A sensitivity analysis based on percent change scores in the above measures also showed no statistically significant differences between the groups (see table in the online data supplement). Side Effects One patient in the ECT plus clozapine group was removed from the study because of recurrence of preexisting involuntary jerky movements that raised clinical concerns of seizure activity. These concerns were not substantiated by electroencephalographic studies. There were no side-effect differences between the two groups in any rated symptom, and there were no treatment-related side effects, except for two occasions when patients in the ECT plus clozapine group were rated as mildly confused and treatment was postponed until the next day. We did not observe any peculiarities in EEG or motor seizure expression, or any prolonged seizures, during ECT. There were no spontaneous seizures among any of the study patients. Cognitive Effects Because of potential concerns about the cognitive side effects of ECT, we included an extensive neurocognitive battery. We assessed multiple cognitive domains, including global mental state, speed of processing, executive function, and episodic memory. The two treatment groups were well matched on Am J Psychiatry 172:1, January 2015 ajp.psychiatryonline.org 55
5 ECT AUGUMENTATION IN CLOZAPINE-RESISTANT SCHIZOPHERNIA TABLE 2. Demographic and Clinical Characteristics of Patients With Clozapine-Resistant Schizophrenia Variable ECT Plus Clozapine Group (N=20) Clozapine Group (N=19) N % N % Sex Male Female Race/ethnicity Caucasian African American Hispanic Other Mean SD Mean SD Age (years) a Brief Psychiatric Rating Scale (BPRS) total score BPRS psychotic symptom subscale score Clinical Global Impressions-severity score Hamilton Depression Rating Scale score Mini-Mental State Examination (MMSE) score Modified MMSE score Clozapine level (ng/ml) a The p value was calculated using Wilcoxon rank-sum test (p=0.03; W=269). FIGURE 2. Changes in Brief Psychiatric Rating Scale (BPRS) Psychosis Subscale Results Over Time a 20 FIGURE 3. Changes in Clinical Global Impressions (CGI)-Severity Scale Ratings Over Time a 8 7 BPRS Total Psychosis CGI Severity Weeks a The graph shows the changes in psychosis symptoms in the clozapine group (blue line; phase 1) and the ECT plus clozapine group (red line; phase 1). Treatment-by-time interaction: F=5.38, df=8, 238, p, The degrees of freedom for mixed-models analysis were obtained using Satterthwaite s method. Error bars represent standard deviations. each of the neurocognitive variables at baseline, including a global measure of cognitive function (using MMSE). Neither group demonstrated a significant change in the global neurocognitive measures tested from baseline to endpoint. The mean MMSE scores for the ECT plus clozapine group were 22.6 (SD=1.2) at baseline and 23.1 (SD=1.2) at week 9, and mean scores for the clozapine group were 22.2 (SD=1.0) and 23.4 (SD=1.2), respectively. Speed measures generally demonstrated significant groupby-time interactions such that the clozapine group improved slightly and the ECT plus clozapine group declined. For tests of visual and verbal memory, significant interaction effects were Weeks a The graph shows the changes in symptom severity in the clozapine group (blue line; phase 1) and the ECT plus clozapine group (red line; phase 1). Treatment-by-time interaction: F=5.00, df=8, 238, p, The degrees of freedom for mixed-models analysis were obtained using Satterthwaite s method. Error bars represent standard deviations. less consistently found. For executive function (Trail-Making Test, Part B, letter-number span task) interaction effects were not found. Results are presented in the second table of the online data supplement. In general, our cognitive findings indicate that speed of processing was sensitive to the effects of ECT administration when measured at a subacute time point (i.e., within 1 week of the final 8-week ECT course). Results in the domains involving executive function and episodic memory were less consistently found. Clinically, the degree of cognitive burden 56 ajp.psychiatryonline.org Am J Psychiatry 172:1, January 2015
6 PETRIDES ET AL. shortly after the trial was felt to be consistent with the clinical experience with ECT. Clozapine Dosage and Plasma Levels The mean clozapine dosage for the ECT treatment group at baseline was mg/day (SD=224.3), and the mean dosage for the clozapine group was mg/day (SD=171.0). There were no significant differences between groups. The clozapine daily doses remained unchanged for each patient throughout the course of the study. There were no significant differences betweengroupsinmeanplasmalevels(clozapineplusnorclozapine) at baseline and at endpoint. ECT The average number of ECT treatments in the randomized phase was 15.8 (SD=4.2), and the average number of treatments in the crossover phase was 14.3 (SD=5.3). The stimulus dose expressed as percent of energy on the Thymatron device is presented in Table 1. The average stimulus levels at the beginning of the course and at the final ECT session are similar to those observed in clinical practice in patients not receiving clozapine. DISCUSSION To our knowledge, this is the first prospective randomized controlled study with masked raters assessing the efficacy of ECT as an augmentation strategy for patients with schizophrenia resistant to or partially responsive to clozapine. The results of this study suggest that ECT is a safe and effective treatment option for these patients and confirm findings from smaller uncontrolled studies and from earlier case reports (11, 12). The response rates of 50% observed in the randomized arm and 47% in the crossover arm compare favorably to all other suggested augmentation strategies for clozapine in this population. The fact that none of the patients in the clozapine group met the response criteria was not unexpected because our selection criteria required a period of at least 8 weeks of clozapine treatment at a steady dose without clinical improvement. The lack of effects with regard to negative symptoms precludes the attribution of response to the improvement of negative symptoms that may often be misinterpreted as depressive symptoms and vice versa. ECT is the oldest biological treatment used in modern psychiatry. It was introduced as a treatment for schizophrenia in the 1930s,atatimewhennomedicationswereavailable.Withthe introduction and widespread use of antipsychotic medications in the 1950s, its use in schizophrenia dramatically declined. Yet, there are certain conditions in the course of the illness when rapid results are required, such as cases with prominent catatonic symptoms, suicidality, and agitation or in cases of neuroleptic malignant syndrome (19). In these cases, ECT is used with very good results. In our study, we demonstrated that ECT also may be useful in patients with chronic schizophrenia with positive symptoms not adequately responsive to antipsychotic medications, including the last resort of pharmacotherapy, clozapine. There are several aspects of our study and its design that are worth mentioning. We paid particular attention to patient selection in an effort to study the effects of ECT on purely schizophrenia patients. We excluded patients with prominent affective symptoms to avoid contamination of our data by improvements driven solely or partially by the treatment of these symptoms that respond to ECT. In order to maintain the blind in a study comparing treatments that are so obviously different, we implemented strict procedures, including videotaping of baseline and exit interviews and independent off-line ratings. We included a crossover arm to strengthen the results observed in the randomized phase. Perhaps the most significant element of the study design was our a priori response criterion. We defined response as a 40% reduction in symptoms based on the psychotic symptom subscale, a level twice as high as the traditional 20% used in most medication-resistant schizophrenia trials. This is in recognition of the fact that the administration of ECT adds additional levels of complexity and risk to the treatment of schizophrenia, requires increased effort by both clinicians and patients, and therefore should be met with increased expectations. The finding that must be emphasized here is that in this group of patients with severe treatment-resistant symptoms, 50% responded with the demanding 40% reduction in symptoms criterion, and 60% responded with conventional response criteria. These are among the highest response rates ever recorded in this patient population. There were several theoretical concerns regarding the concurrent use of ECT and clozapine, most notably the possibility of prolonged or spontaneous seizures. In our sample, we did not observe any such occurrences. On the contrary, there were instances that required us to administer stimuli at 100% of the device capacity in order to elicit an adequate seizure. This over-time increased resistance to seizure induction is in line with clinical experience and reflects the fact that ECT has known antiepileptic properties causing the seizure threshold to increase over the course of ECT treatment. With regard to the cognitive effects of the combined treatment, we did not observe any unusual effects of ECT. Our patients were severely ill, and their cognitive performance was, as expected, relatively low, with an average baseline MMSE score of 22. The fact that there was no additional impairment after the course of ECT may reflect the fact that some aspects of cognitive function improved as a result of decreased disorganization, thus counteracting the expected transient memory impairment often seen with ECT. There are limitations of the study that need to be addressed. First, there was no placebo arm, since sham ECT studies are not considered ethical. Second, the number of patients was relatively low, and our sample included only inpatients. However, this is the largest study of this nature, and the comparative effects between the two groups are very strong. Third, there was an age difference between the two groups, with the clozapine group being older. One might assume that this may make symptoms in this group more resistant to treatment. Nevertheless, all group differences remained significant after Am J Psychiatry 172:1, January 2015 ajp.psychiatryonline.org 57
7 ECT AUGUMENTATION IN CLOZAPINE-RESISTANT SCHIZOPHERNIA correcting for age, and, more importantly, the older clozapine group had an equally strong response to ECT in the crossover phase. Finally, the duration of the study was relatively short and did not allow for conclusions regarding the long-term effects of ECT in this population. As in the case of the treatment of depression with ECT, it is likely that maintenance treatment is required for those patients who respond to ECT plus clozapine, but this should be the focus of further research. CONCLUSIONS The augmentation of clozapine with ECT for the treatment of clozapine-resistant schizophrenia is a safe and effective treatment option. In this severely ill group of patients with treatment-resistant symptoms, for whom there are few clinical alternatives, we demonstrated a 50% response rate using a conservative 40% reduction in symptoms criterion, and 60% response rate using conventional response criteria. To our knowledge, these are the highest response rates reported with any type of clozapine augmentation. Further research is required to determine the persistence of the results and the need for maintenance treatments. AUTHOR AND ARTICLE INFORMATION From the Division of Psychiatry Research, The Zucker Hillside Hospital, North Shore-LIJ Health System, Glen Oaks, N.Y., and The Feinstein Institute for Medical Research, Manhasset, N.Y. Address correspondence to Dr. Petrides (Petrides@lij.edu). Supported by an RO1 grant from NIMH to Dr. Petrides (MH ). The authors thank Dr. Max Fink for his contribution to the conceptualization of the study, mentorship, support, and tireless enthusiasm for this line of research. Dr. Petrides has received research support from Amgen, Astra Zeneca, Corcept, Eli Lilly, NIMH, Proteus, St. Jude Medical, and Sunovion, and he has served on an advisory panel for Corcept. Dr. Schooler has received honorarium from Lundbeck, advisory board honoraria from Amgen, Eli Lilly, EnVivo, Janssen Psychiatry, Roche, and Sunovion, and research grant support from Genentech, Neurocrine, and Otsuka. Dr. Malhotra has served as a consultant to Genomind. Dr. Kane has served as a consultant to or on the advisory board or speaker s bureau of Alkermes, Bristol-Myers Squibb, Eli Lilly, Forest, FORUM, Genentech, H. Lundbeck, Intracellular Therapeutics, Janssen, Johnson and Johnson, Otsuka, Reviva, and Roche, and he is a shareholder with MedAvante. All other authors report no financial relationships with commercial interests. Received June 17, 2013; revisions received Feb. 25 and May 5, 2014; accepted June 6, REFERENCES 1. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, Kulhanek F, Liberman RP, Malm U, Midha KK: Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16: Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatmentresistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: Meltzer HY, Bastani B, Kwon KY, Ramirez LF, Burnett S, Sharpe J: A prospective study of clozapine in treatment-resistant schizophrenic patients, I: preliminary report. Psychopharmacology (Berl) 1989; 99 (suppl):s68 S72 5. Barbui C, Signoretti A, Mulè S, Boso M, Cipriani A: Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009; 35: Cipriani A, Boso M, Barbui C: Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev 2009; 3:CD Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S: Antipsychotic combinations vs monotherapy in schizophrenia: a metaanalysis of randomized controlled trials. Schizophr Bull 2009; 35: Taylor DM, Smith L: Augmentation of clozapine with a second antipsychotic: a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009; 119: Braga RJ, Petrides G: The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. J ECT 2005; 21: Kupchik M, Spivak B, Mester R, Reznik I, Gonen N, Weizman A, Kotler M: Combined electroconvulsive-clozapine therapy. Clin Neuropharmacol 2000; 23: Kho KH, Blansjaar BA, de Vries S, Babuskova D, Zwinderman AH, Linszen DH: Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia: an open label study. Eur Arch Psychiatry Clin Neurosci 2004; 254: Havaki-Kontaxaki BJ, Ferentinos PP, Kontaxakis VP, Paplos KG, Soldatos CR: Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. Clin Neuropharmacol 2006; 29: Masoudzadeh A, Khalilian AR: Comparative study of clozapine, electroshock and the combination of ECT with clozapine in treatment-resistant schizophrenic patients. Pak J Biol Sci 2007; 10: Woerner MG, Mannuzza S, Kane JM: Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988; 24: Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, Md, US Department of Health, Education, and Welfare, Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: Spitzer RL, Williams JBW, Gibbon M, First MB: Structured Clinical Interview for DSM-IV (SCID). New York, New York State Psychiatric Institute, Biometrics Research, Andreasen NC, Olsen S: Negative v positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982; 39: Weiner RD, Coffey C, Fochtmann L: The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging: A Task Force Report of the American Psychiatric Association, 2nd ed. Washington, DC, American Psychiatric Publishing, ajp.psychiatryonline.org Am J Psychiatry 172:1, January 2015
Charles H. Kellner, MD
ECT: Learning From Recent Trials Charles H. Kellner, MD Professor, Department of Psychiatry Icahn School of Medicine at Mount Sinai ISCTM Philadelphia, PA 27 September, 2016 Charles H. Kellner, MD Disclosures
More informationPositive and Negative Symptom Response to Clozapine in Schizophrenic Patients With and Without the Deficit Syndrome
BUCHANAN, POSITIVE Am J Psychiatry AND BREIER, NEGATIVE 155:6, KIRKPATRICK, June SYMPTOM 1998 ET RESPONSE AL. Positive and Negative Symptom Response to Clozapine in Schizophrenic With and Without the Deficit
More informationAre they still doing that?
Are they still doing that? Why we still give ECT and when to refer Nicol Ferrier BSc (Hons), MD, FRCP(Ed), FRCPsych Emeritus Professor of Psychiatry Newcastle University Rates of prescribing ECT in the
More informationNovember 2014 MRC2.CORP.X.00004
This program is paid for by Otsuka America Pharmaceutical, Inc. and Lundbeck, LLC. The speaker is a paid consultant of Otsuka America Pharmaceutical, Inc. advice or professional diagnosis. Users seeking
More informationECT in Schizophrenia. Dr Richard Braithwaite Consultant Psychiatrist Isle of Wight NHS Trust
ECT in Schizophrenia Dr Richard Braithwaite Consultant Psychiatrist Isle of Wight NHS Trust ECT in Schizophrenia (not catatonia) Dr Richard Braithwaite Consultant Psychiatrist Isle of Wight NHS Trust Objectives
More informationRole of Clozapine in Treatment-Resistant Schizophrenia
Disease Management and Treatment Strategies Elkis H, Meltzer HY (eds): Therapy-Resistant Schizophrenia. Adv Biol Psychiatry. Basel, Karger, 2010, vol 26, pp 114 128 Role of Clozapine in Treatment-Resistant
More informationAntipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD
Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD Professor of Psychiatry and Molecular Medicine Hofstra North Shore - LIJ School of Medicine
More informationPresented at the American Psychiatric Association Annual Meeting May 20 24, 2017 San Diego, CA.
Original Presentations Key Words: amines, antipsychotic agents, double-blind method, mood disorders, psychopharmacology, psychotic disorders, schizophrenia, tardive dyskinesia, valbenazine Efficacy of
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-USA-232 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-USA-232 Title of Study: Efficacy and Safety of a Flexible Dose of Risperidone Versus Placebo in the Treatment of Psychosis of Alzheimer's Disease Principal Investigator: M.D.
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationSuboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies
Suboptimal Response in Psychotic & Mood Disorders: Causes, Consequences, and Management Strategies Henry A. Nasrallah, MD Sydney W. Souers Professor and Chair, Department of Psychiatry, Saint Louis University,
More informationEfficacy of electroconvulsive therapy augmentation for partial response to clozapine: a pilot randomized ECT sham controlled trial
Original article Efficacy of electroconvulsive therapy augmentation for partial response to clozapine: a pilot randomized sham controlled trial Debora Luciana Melzer-Ribeiro 1, Sergio Paulo Rigonatti 1,
More informationRepeatable Battery for the Assessment of Neuropsychological Status as a Screening Test in Schizophrenia, I: Sensitivity, Reliability, and Validity
Repeatable Battery for the Assessment of Neuropsychological Status as a Screening Test in Schizophrenia, I: Sensitivity, Reliability, and Validity James M. Gold, Ph.D., Caleb Queern, B.A., Virginia N.
More informationTHE HAMILTON Depression Rating Scale
Reliability and Validity of the Turkish Version of the Hamilton Depression Rating Scale A. Akdemir, M.H. Türkçapar, S.D. Örsel, N. Demirergi, I. Dag, and M.H. Özbay The aim of the study was to examine
More informationAPRIL 2008 DELHI PSYCHIATRY JOURNAL Vol. 11 No.1. Harish Arora, Rajdeep Kaur Department of Psychiatry, G.G.S. Medical College, Faridkot, Punjab
APRIL 2008 DELHI PSYCHIATRY JOURNAL Vol. 11 No.1 Original Article An Open Label Study on Amisulpride in Augmentation with Atypical Antipsychotics in Treatment Resistant Patients of Schizophrenia and Schizoaffective
More information1. Introduction Overview Organization of Executive Summary
Executive Summary and Discussion of the Vagus Nerve Stimulation (VNS) Therapy Depression Indication Clinical Data (Updated to Include Information from Deficiency Letter Response) Prepared By: Richard L.
More information(+)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]-ethyl]- 6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyridol[1,2-a]pyrimidin-4- one
SYNOPSIS Issue Date: 18 November 2008 Document No.: EDMS-PSDB-9006510:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Ortho-McNeil Janssen Scientific Affairs, L.L.C. Paliperidone
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationChapter 1.4. Intermittent neuroleptic treatment is a risk factor for tardive dyskinesia
Intermittent neuroleptic treatment is a risk factor for tardive dyskinesia The Curaçao Extrapyramidal Syndromes Study: III. Peter N. van Harten (1,3), Hans W. Hoek (2), Glenn E. Matroos (3), Maarten Koeter
More informationVO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT)
VO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT) Diagnostic Guidelines: Introduction: Electroconvulsive Therapy has been in continuous use for more than 60 years. The clinical literature
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationScottish Medicines Consortium
Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish
More informationI received help from Bosch Health Care
John Kasckow, MD, PhD VA Pittsburgh Health Care System Western Psychiatric Institute and Clinic, UPMC VA Pittsburgh Health Care System I received help from Bosch Health Care 1 Diagnoses of Interest Early
More informationRecent Advances in the Antipsychotic Treatment of People with schizophrenia. Robert W. Buchanan, M.D.
Recent Advances in the Antipsychotic Treatment of People with schizophrenia Robert W. Buchanan, M.D. Antipsychotic medications are the primary class of drugs used in the pharmacological treatment of schizophrenia.
More informationPROVIDED IN RESPONSE TO YOUR UNSOLICITED REQUEST FOR INFORMATION
KINECT 2 NCT01733121 Baseline Week 2 Week 4 Week 6 Valbenazine 25-75 mg Valbenazine 40 mg KINECT 3 NCT02274558 Valbenazine 80 mg a KINECT 2 and KINECT 3 were 6-week, double-blind placebo-controlled trials
More informationRESEARCH UPDATES: Improving Functioning In Schizophrenia?
RESEARCH UPDATES: Improving Functioning In Schizophrenia? Stephen R. Marder, MD Professor and Director, Section on Psychosis Semel Institute for Neuroscience and Human Behavior at UCLA Director, Mental
More informationUniversity of Groningen
University of Groningen A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole Schorr, S. G.; Slooff, C. J.; Postema, R.; Van Oven, W.; Schilthuis, M.; Bruggeman, Richard;
More informationProspective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors
Prospective Study of Tardive Dyskinesia in the Elderly: Rates and Risk Factors Margaret G. Woerner, Ph.D., Jose Ma. J. Alvir, Dr.P.H., Bruce L. Saltz, M.D., Jeffrey A. Lieberman, M.D., and John M. Kane,
More informationA Pilot Study of Interpersonal Psychotherapy for Depressed Women with Breast Cancer
A Pilot Study of Interpersonal Psychotherapy for Depressed Women with Breast Cancer CARLOS BLANCO, M.D., Ph.D.* JOHN C. MARKOWITZ, M.D.* DAWN L. HERSHMAN, M.D., M.S.# JON A. LEVENSON, M.D.* SHUAI WANG,
More informationRUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1
RUNNING HEAD: Efficacy, Long Acting Injectable Antipsychotics and Schizophrenia 1 Efficacy of Long Acting Injectable Antipsychotics in Early Onset Schizophrenia Linda Pietras RN-BC Mercyhurst University
More informationA 52-week, randomized, open-label study of aripiprazole versus blonanserin in the treatment of Japanese schizophrenia patients
Original Contribution CNPT8(2017)16-24 A 52-week, randomized, open-label study of aripiprazole versus blonanserin in the treatment of Japanese schizophrenia patients Asuka Katsuki, Hikaru Hori, Kiyokazu
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSummary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ
CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center
More informationPsychopathology in patients with schizophrenia attending a psychiatry outpatient clinic at a tertiary care hospital
Original paper Psychopathology in patients with schizophrenia attending a psychiatry outpatient clinic at a tertiary care hospital Hiranya Wijesundara, Madhubhashinee Dayabandara, Arjuna Ellepola and Raveen
More informationOUTCOMES OF DICHOTOMIZING A CONTINUOUS VARIABLE IN THE PSYCHIATRIC EARLY READMISSION PREDICTION MODEL. Ng CG
ORIGINAL PAPER OUTCOMES OF DICHOTOMIZING A CONTINUOUS VARIABLE IN THE PSYCHIATRIC EARLY READMISSION PREDICTION MODEL Ng CG Department of Psychological Medicine, Faculty of Medicine, University Malaya,
More informationExplanatory Attributions of Anxiety and Recovery in a Study of Kava
THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 10, Number 3, 2004, pp. 556 559 Mary Ann Liebert, Inc. Explanatory Attributions of Anxiety and Recovery in a Study of Kava KURIAN C. ABRAHAM,
More informationThe Tides of Change: Implementing Early Onset Psychosis Services with a National Thought Leader
The Tides of Change: Implementing Early Onset Psychosis Services with a National Thought Leader John M. Kane, M.D. Professor and Chairman Department of Psychiatry Hofstra North Shore-LIJ School of Medicine
More informationClozapine Treatment and Predictors of Response in Patients with Schizophrenia
KISEP Original Article Clinical Psychopharmacology and Neuroscience 2003; 1: 22-6 Clozapine Treatment and Predictors of Response in Patients with Schizophrenia Chul Eung Kim, Sang Eun Shin, Min Hee Kang
More informationComparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Clozapine and long acting antipsychotics
Research Comparison of pre-treatment clinical characteristics and post-treatment outcomes of patients treated with Dante M Durand,1, Phillip Harvey 1,2, Ricardo Cáceda 3 ABSTRACT Introduction: Clozapine
More informationBizarre delusions and DSM-IV schizophrenia
Psychiatry and Clinical Neurosciences (2002), 56, 391 395 Regular Article Bizarre delusions and DSM-IV schizophrenia MAKOTO NAKAYA, md, phd, 1 KATSUNORI KUSUMOTO, md, phd, 2 TAKAYUKI OKADA, md, phd 3 AND
More informationADMINISTRATIVE POLICY AND PROCEDURE
Page 1 of 6 SECTION: Medical SUBJECT: Electroconvulsive Therapy (ECT) DATE OF ORIGIN: 10/1/96 REVIEW DATES: 7/1/98, 10/1/99, 7/1/02, 7/1/04, 10/1/05, 5/1/09, 1/3/13, 7/1/15, 8/1/16 EFFECTIVE DATE: 3/24/17
More informationIs Aristada (Aripiprazole Lauroxil) a Safe and Effective Treatment For Schizophrenia In Adult Patients?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 12-2016 Is Aristada (Aripiprazole Lauroxil)
More informationAre Two Antipsychotics Better Than One?
Are Two Antipsychotics Better Than One? Lauren Hanna, M.D and Delbert Robinson, M.D. Northwell Health National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office
More informationJanssen-Cilag EMEA Medical Affairs a division of Janssen Pharmaceuticals N.V.
SYNOPSIS Issue Date: Final 22 July 2009 [Document No.: EDMS-PSDB-9245102] Name of Sponsor/Company Name of Finished Product Risperdal Consta Name of Active Ingredient(s) Protocol No.: RIS-BMN-3001 Janssen-Cilag
More informationBackground. Population/Intervention(s)/Comparator/Outcome(s) (PICO) Duration of antipsychotic treatment in individuals with a first psychotic episode
updated 2012 Duration of antipsychotic treatment in individuals with a first psychotic episode Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug
More informationDiagnostic orphans for alcohol use disorders in a treatment-seeking psychiatric sample
Available online at www.sciencedirect.com Drug and Alcohol Dependence 96 (2008) 187 191 Short communication Diagnostic orphans for alcohol use disorders in a treatment-seeking psychiatric sample Lara A.
More informationClinical Guidelines for the Pharmacologic Treatment of Schizophrenia
Clinical Guidelines for the Pharmacologic Treatment of Community Behavioral Health (CBH) is committed to working with our provider partners to continuously improve the quality of behavioral healthcare
More informationAdult Mental Health Services applicable to Members in the State of Connecticut subject to state law SB1160
Adult Mental Health Services Comparison Create and maintain a document in an easily accessible location on such health carrier's Internet web site that (i) (ii) compares each aspect of such clinical review
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: CR004357 Title of Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 and 100 mg eq. of Paliperidone Palmitate in Subjects With
More informationSupplementary Online Content
Supplementary Online Content Lam RW, Levitt AJ, Levitan RD, et al. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized
More informationSYNOPSIS. Risperidone-R064766: Clinical Study Report RIS-INT-24 (FOR NATIONAL AUTHORITY USE ONLY)
SYNOPSIS Protocol No.: RIS-INT-24 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: Risperidone in the treatment of behavioral disturbances in demented patients: an international, multicenter,
More informationCondensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia
Condensed Clinical Practice Guideline Treatment Of Patients With Schizophrenia I. Key Points a. Schizophrenia is a chronic illness affecting all aspects of person s life i. Treatment Planning Goals 1.
More informationPaliperidone: Clinical Protocol R076477SCH4012, CR Amendment INT-1
Paliperidone: Clinical Protocol R076477SCH4012, CR013771 Amendment INT-1 A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed
More informationSuicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative
Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic
More informationPanic disorder and anxiety symptoms are hypothesized
Article Anxiety in Major Depression: Relationship to Suicide Attempts Giovanni P.A. Placidi, M.D. Maria A. Oquendo, M.D. Kevin M. Malone, M.D. Beth Brodsky, Ph.D. Steven P. Ellis, Ph.D. J. John Mann, M.D.
More informationReprinted from the German Journal of Psychiatry ISSN Worrawat Chanpattana
Reprinted from the German Journal of Psychiatry http://www.gjpsy.uni-goettingen.de ISSN 1433-1055 Seizure Threshold in Electroconvulsive Therapy: Effect of Instrument Titration Schedule Worrawat Chanpattana
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients with Bipolar Disorder
Zahedan Journal of Research in Medical Sciences Journal homepage: www.zjrms.ir The Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients
More informationThe outlook for schizophrenia is better than we think but is being sabotaged by Assembly-line Psychiatry
The outlook for schizophrenia is better than we think but is being sabotaged by Assembly-line Psychiatry Robin M Murray Department of Psychosis Studies Institute of Psychiatry King s College London robin.murray@kcl.ac.uk
More informationR (paliperidone palmitate) Clinical Study Report R SCA-3004
SYNOPSIS Name of Sponsor/Company Janssen Scientific Affairs, LLC Name of Finished Product INVEGA SUSTENNA Name of Active Ingredient(s) Status: Approved Date: 10 March 2014 Prepared by: Janssen Scientific
More informationPage 1 of 18 Volume 01 Page 1
Response to Vagus Nerve Stimulation (VNS) Therapy Treatment-Resistant Depression (TRD) Indication Not Approvable Letter from the United States Food and Drug Administration (FDA), Dated August 11, 2004
More informationEarly response as predictor of final remission in elderly depressed patients
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry (2009) Published online in Wiley InterScience (www.interscience.wiley.com).2261 Early response as predictor of final remission in
More informationSCHRES1520. Schizophrenia Research 000 (2001) 000±000. Affective reactivity of language and right-ear advantage in schizophrenia
SCHRES1520 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 Abstract Affective reactivity of language and right-ear
More informationAdvisory Boards -- Dainippon Sumito Pharma; Takeda and Lundbeck. Off-label data included for Mirapex (pramipexole)
Disclosures Advisory Boards -- Dainippon Sumito Pharma; Takeda and Lundbeck Off-label data included for Mirapex (pramipexole) Funding from NIMH; Stanley Medical Research Institute; NARSAD A Brief History
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION ARIPIPRAZOLE LONG-ACTING INJECTION (Abilify Maintena Otsuka Pharmaceuticals Co. & Lundbeck Canada Inc.) Indication: Schizophrenia Recommendation: The Canadian Drug Expert Committee
More informationSchizophrenia* London, Ontario, Canada Submitted: July 26, Accepted: November 18,1993. risperidone brought some
CASE REPORT Famotidine as an Adjunct Treatment of Resistant Schizophrenia* L.K. Oyewumi, D. Vollick, H. Merskey and C. Plumb Department of Psychiatry, University of Western Ontario, London Psychiatric
More informationRepetitive transcranial magnetic stimulation for depression
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Repetitive transcranial magnetic stimulation for depression Depression causes low mood or sadness that can
More informationSYNOPSIS. Trial identification and protocol summary
SYNOPSIS Trial identification and protocol summary Company: JANSSEN PHARMACEUTICA N.V. Finished product: Risperdal Active ingredient: Risperidone (R64766) Title: The safety and efficacy of risperidone
More informationRegulatory Challenges in Targeting Cognitive Impairment in Depression. Thomas Laughren, M.D. Director, Regulatory Affairs MGH CTNI
Regulatory Challenges in Targeting Cognitive Impairment in Depression Thomas Laughren, M.D. Director, Regulatory Affairs MGH CTNI 1 Current & Past Consulting Relationships Part time employee of MGH CTNI
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationThe New Clinical Science of ECT
The New Clinical Science of ECT C. Edward Coffey, MD Professor of Psychiatry & Behavioral Sciences, and of Neurology Baylor College of Medicine Houston, Texas Fellow and Past President, International Society
More informationDouble-Blind Comparison of Olanzapine versus Clozapine in Schizophrenic Patients Clinically Eligible for Treatment with Clozapine
Double-Blind Comparison of Olanzapine versus Clozapine in Schizophrenic Patients Clinically Eligible for Treatment with Clozapine Gary D. Tollefson, Martin A. Birkett, Gerilyn M. Kiesler, Andrew J. Wood,
More informationWhat s new in the treatment of bipolar disorder?
What s new in the treatment of bipolar disorder? Dr. David Cousins MRC Clinician Scientist Institute of Neuroscience Newcastle University NCMD 2017 What s new in the treatment of bipolar disorder? Dr.
More informationThe Adolescent with ADHD: Managing Transition
The Adolescent with ADHD: Managing Transition Professor Philip Hazell University of Sydney and Rivendell Child, Adolescent and Family Mental Health Service Disclosure Statement: Philip Hazell Source Eli
More informationWorking with Clients Experiencing a First Episode of Psychosis: Considerations for Prescribers
Working with Clients Experiencing a First Episode of Psychosis: Considerations for Prescribers Tuesday, February 23, 2016 2pm Eastern Delbert Robinson, M.D. Professor of Psychiatry and Molecular Medicine
More informationSupplementary Online Content
Supplementary Online Content Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia:
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIn the general population, men are more physically aggressive
Article Gender Differences in Violent Behaviors: Relationship to Clinical Symptoms and Psychosocial Factors Menahem Krakowski, M.D., Ph.D. Pal Czobor, Ph.D. Objective: Men are more violent than women in
More informationarxiv: v1 [q-bio.nc] 9 Dec 2011
Long Brief Pulse Method for Pulse-wave modified Electroconvulsive Therapy Hiroaki Inomata, 1,2,3, Hirohiko Harima, 1 and Masanari Itokawa 1,3 1 Tokyo Metropolitan Matsuzawa Hospital 2 Yokohama City University
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationClozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders
Neuropsychobiology 2002;45(suppl 1):37 42 Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders A Case Series B. Hummel S. Dittmann A. Forsthoff N. Matzner
More informationTHERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA THERAPEUTIC AND EVOLUTIVE ASPECTS IN SCHIZOPHRENIA ABSTRACT Ph.D. Coordinator Professor Dragoș MARINESCU PhD Student: Mihai MUTICĂ Craiova 2016 TABLE OF CONTENTS
More informationSetting The setting was primary and secondary care. The economic evaluation was conducted in France.
Cost-effectiveness of mirtazapine relative to fluoxetine in the treatment of moderate and severe depression in France Brown M C, van Loon J M, Guest J F Record Status This is a critical abstract of an
More informationMulti-Dimensional Family Therapy. Full Service Partnership Outcomes Report
MHSA Multi-Dimensional Family Therapy Full Service Partnership Outcomes Report TABLE OF CONTENTS Enrollment 5 Discontinuance 5 Demographics 6-7 Length of Stay 8 Outcomes 9-11 Youth Outcome Questionnaire
More informationEFFECTS OF PHARMACOLOGICAL TREATMENTS ON COGNITION
EFFECTS OF PHARMACOLOGICAL TREATMENTS ON COGNITION Richard Keefe, PhD Professor of Psychiatry & Behavioral Sciences and Psychology & Neuroscience Duke University Medical Center Enabling Discovery, Development,
More informationClinician-reported Outcomes (ClinROs), Concepts and Development
Clinician-reported Outcomes (ClinROs), Concepts and Development William Lenderking, PhD, Senior Research Leader; Dennis Revicki, PhD, Senior Vice President, Outcomes Research In heathcare, there are many
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationRegulatory Issues in Targeting Cognitive Impairment in Depression. Thomas Laughren, M.D. Director, Regulatory Affairs MGH CTNI
Regulatory Issues in Targeting Cognitive Impairment in Depression Thomas Laughren, M.D. Director, Regulatory Affairs MGH CTNI 1 Current Financial Relationships Part time employee of MGH CTNI Consultant
More informationCopyright 2002 American Academy of Neurology. Volume 58(8) 23 April 2002 pp
Copyright 2002 American Academy of Neurology Volume 58(8) 23 April 2002 pp 1288-1290 Improved executive functioning following repetitive transcranial magnetic stimulation [Brief Communications] Moser,
More informationAugmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A
Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: A systematic review and meta-analysis Authors: John Lally, John Tully, Dene Robertson, Brendon Stubbs, F Gaughran*
More informationCHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there
More informationANXIOUS DEPRESSION. Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University
ANXIOUS DEPRESSION Ned H. Kalin, MD University of Wisconsin Alan F. Schatzberg, MD Stanford University NED H. KALIN, MD Disclosures!! Research/Grants: None!! Speakers Bureau: None!! Consultant: None!!
More informationA Coding System to Measure Elements of Shared Decision Making During Psychiatric Visits
Measuring Shared Decision Making -- 1 A Coding System to Measure Elements of Shared Decision Making During Psychiatric Visits Michelle P. Salyers, Ph.D. 1481 W. 10 th Street Indianapolis, IN 46202 mpsalyer@iupui.edu
More informationMethod. NeuRA Schizophrenia and bipolar disorder April 2016
Introduction Schizophrenia is characterised by positive, negative and disorganised symptoms. Positive symptoms refer to experiences additional to what would be considered normal experience, such as hallucinations
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationPsychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com
Psychotic disorders Dr. Sarah DeLeon, MD PGYIV, Psychiatry ConceptsInPsychiatry.com Introduction Psychotic spectrum disorders include schizotypal personality disorder, delusional disorder, brief psychotic
More information